Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

Learn more about:
Related Clinical Trial
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers Assessment of Patients’ Quality of Sexual Life After Anal Cancer Treatment Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5) Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors Detecting HPV DNA in Anal and Cervical Cancers ANCA II – Quality of Life and Functional Outcome in Patients With Anal Cancer RTX-321 Monotherapy in Patients With HPV 16+ Tumors Anal Injury Screening for High Risk HPV M7824 in Subjects With HPV Associated Malignancies Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Function Following Laser for Anal Intraepithelial Neoplasia (FLAN) A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery? Drainage Seton With Flap Versus EAS Preserving Seton in Treatment of Transsphincteric Anal Fistula HPV-SAVE: 9-Valent HPV Vaccine for High-Grade Anal Dysplasia Radiation Dosimetry Study Comparing 2 Different Patient Setups in Anal/Rectal Cancer Patients Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men High-Resolution Anoscopy Perceived Discomfort Study Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia Image Fusion PET, CT and 3D-ultrasound Examinations Hybrid Capture 2 Human Papiloma Virus (HPV) High-Risk Anal DNA Test ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV Molecular Genetic and Pathological Studies of Anal Tumors Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic Radiotherapy Screening for HIV-Associated Anal Cancer Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE) Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer Prospective Cohort on Quality of Sexual Life Among Men Who Have Sex With Men Treated for Anal Cancer With Concurrent Chemotherapy and Intensity-modulated Radiotherapy Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Anal Cancer Radiotherapy Study Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer Individual Following in Anal Cancer With PET/CT Anal Cancer Screening Study The Prevent Anal Cancer Self-Swab Study Shared Decision Making With Anal Cancer Patients on Radiation Dose Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy Quality of Life in Patients With Anal Cancer Functional Outcomes Following Anal Cancer Treatment Pembrolizumab in Refractory Metastatic Anal Cancer A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer

Brief Title

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

Official Title

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.

Brief Summary

      The RADIANCE multicenter, randomized phase II trial will assess the efficacy of durvalumab, a
      PD-L1 immune checkpoint inhibitor, in combination with primary mitomycin C
      (MMC)/5-fluorouracil (5-FU)-based radiochemotherapy (RCT) in patients with locally-advanced
      anal squamous cell carcinoma (ASCC).
    

Detailed Description

      Anal squamous cell carcinomas (ASCC) are increasing in frequency across the developed world.
      There is a strong rationale for combining the PD-L1 immune checkpoint inhibitor durvalumab
      with radiochemotherapy (RCT) in patients with ASCC. First, although primary RCT with
      concurrent mitomycin C and 5-fluorouracil (MMC/5-FU) is the standard treatment for ASCC, the
      3-year DFS in patients with locally-advanced disease is only in the range of 60%. Second,
      approximately 80-90% of patients with ASCC are human papilloma virus (HPV)-positive, which is
      associated with higher tumor "immunogenicity" in this malignancy that is known to correlate
      with better response to RCT as well as PD-1/PD-L1 immune checkpoint inhibitors. Also, PD-L1
      expression was observed in 33%-62% of patients with locally advanced non-metastatic ASCC that
      correlated with tumor stage. Third, inhibition of the PD-1/PD-L1 axis showed encouraging
      responses in recurrent/metastatic ASCC in two phase Ib/II trials. Fourth, several data
      indicate complementary roles between R(C)T and immunotherapy. Fifth, R(C)T can induce PD-L1
      upregulation with resulting dysfunction in CD8+ T-cells, and addition of anti-PD-L1 to R(C)T
      can overcome T-cell suppression to reinvigorate immune surveillance. First clinical studies
      have demonstrated promising findings for the combination of RCT and immunotherapies. Thus,
      based on the above data, RCT combined with durvalumab is expected to be more effective than
      primary RCT alone. Altogether, the hereby proposed RADIANCE multicenter, randomized phase II
      trial aims to improve the current standard treatment by incorporating durvalumab to the
      primary MMC/5-FU-based RCT in patients with locally-advanced ASCC (T2=>4cm Nany, stage
      IIB-IIIC).
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Disease-free survival (DFS)

Secondary Outcome

 Major adverse events

Condition

Anal Cancer

Intervention

Chemotherapy

Study Arms / Comparison Groups

 5FU+Mitomycin C
Description:  Radiochemotherapy for anal cancer

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

178

Start Date

January 15, 2020

Completion Date

June 30, 2026

Primary Completion Date

March 31, 2023

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically-confirmed ASCC (both genders) of the anal canal or the anal margin

          -  UICC-Stage IIB-IIIC including T2>4cm Nany (IIB: T3N0M0; IIIA: T1-2N1M0; IIIB: T4N0M0;
             IIIC: T3-4N1M0; T2>4cm Nany) according to proctoscopy, pelvic MRI, CT scan of thorax
             and abdomen, all within 30 days prior to recruitment

          -  Age ≥ 18 years, no upper age limit

          -  ECOG-Performance score 0-1

          -  History/physical examination within 30 days prior to recruitment

          -  Written informed consent and any locally-required authorization (e.g. EU Data Privacy
             Directive in the EU) obtained from the patient prior to performing any
             protocol-related procedures, including screening evaluations

          -  Life expectancy of > 12 months

          -  Body weight >30kg

          -  Hemoglobin ≥9.0 g/dl

          -  Leukocytes >3.5 x 10 ^9/l

          -  Absolute neutrophil count (ANC) 1.5 x 10 9/l (> 1500 per mm3)

          -  Platelet count ≥100 x 109/l (>100,000 per mm3)

          -  Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN). (This will not apply
             to patients with confirmed Gilbert's syndrome (persistent or recurrent
             hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or
             hepatic pathology), who will be allowed only in consultation with their physician.

          -  AST (SGOT), ALT (SGPT), AP ≤ 3x institutional ULN

          -  Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula creatinine clearance

          -  Female subject of childbearing potential should have a negative serum pregnancy within
             72 hours prior to receiving the first dose of durvalumab. A highly sensitive pregnancy
             test must be used.

          -  Female subjects of childbearing potential must be willing to use a highly effective
             contraceptive measure as defined in the Clinical Trial Facilitation Group (CTFG)
             guideline ("Recommendations related to contraception and pregnancy testing in clinical
             trials"). Highly effective contraception is required from screening to 90 days after
             the last dose of durvalumab. (Note: Abstinence is acceptable if this is the usual
             lifestyle and preferred contraception for the subject.)

          -  Male subjects of childbearing potential must agree to use a highly effective method of
             contraception, starting from screening to 90 days after the last dose of durvalumab.
             (Note: Abstinence is acceptable if this is the usual lifestyle and preferred
             contraception for the subject.) Male patients should refrain from fathering a child or
             donating sperm during the study and for 180 days after the last dose of durvalumab +
             any drug combination therapy or 90 days after the last dose of durvalumab monotherapy,
             whichever is the longer time period.

          -  Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up.

          -  For HIV-positive patients: running combined antiretroviral therapy (CART) on a stable
             dose at study entry and undetectable HIV-viral load (HIV Viral load <50 copies/mL and
             CD4>200/Mircoliter). Patients will be closely monitored and CART management will be
             performed according to appropriate labelling guidance of the antiviral therapy. CART
             should be on a stable dose at study entry.

        Exclusion Criteria:

          -  UICC-Stage I-IIA ASCC defined as cT1N0M0 or cT2 <4cm N0M0 disease

          -  Second malignancy other than basalioma or cervical/genital/ neoplasia in situ

          -  History of another primary malignancy except for:

               -  Malignancy treated with curative intent and with no known active disease ≥5 years
                  before the first dose of durvalumab and of low potential risk for recurrence

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease

               -  Adequately treated carcinoma in situ without evidence of disease

          -  Known DPD-deficiency

          -  Participation in another clinical study with an investigational product during the
             last 12 months

          -  Concurrent enrolment in another clinical study, unless it is an observational
             (non-interventional) clinical study or during the follow-up period of an
             interventional study

          -  Any previous treatment with other immunotherapy, a PD1 or PD-L1 inhibitor

          -  QT interval corrected for heart rate (QTc) ≥470 ms

          -  Current or prior use of immunosuppressive medication within 14 days before the first
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/d of
             prednisone, or an equivalent corticosteroid. In case of recent introduction of CART,
             inclusion will be possible provided subjects had at least 4 weeks of treatment prior
             to inclusion.

          -  Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion
             criteria:

               -  Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after
                  consultation with the Study Chairman.

               -  Patients with irreversible toxicity not reasonably expected to be exacerbated by
                  treatment with durvalumab may be included only after consultation with the Study
                  Chairman

          -  Any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment, other
             than the study medication. Concurrent use of hormonal therapy for non-cancer-related
             conditions (e.g., hormone replacement therapy) is acceptable.

          -  Previous radiotherapy treatment to the pelvis or radiotherapy treatment to more than
             30% of the bone marrow or with a wide field of radiation within 4 weeks of the first
             dose of study drug

          -  Major surgical procedure (as defined by the Investigator) within 28 days prior to the
             first dose of durvalumab.

          -  History of allogenic organ transplantation.

          -  Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this
             criterion:

               -  Patients with vitiligo or alopecia

               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
                  hormone replacement

               -  Any chronic skin condition that does not require systemic therapy

               -  Patients without active disease in the last 5 years may be included but only
                  after consultation with the study chairman

               -  Patients with celiac disease controlled by diet alone

          -  Uncontrolled intercurrent illness, including but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic
             gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social
             situations that would limit compliance with study requirement, substantially increase
             risk of incurring AEs or compromise the ability of the patient to give written
             informed consent

          -  History of leptomeningeal carcinomatosis or any other metastatic disease

          -  History of active primary immunodeficiency

          -  Active infection including tuberculosis (clinical evaluation that includes clinical
             history, physical examination and radiographic findings, and TB testing in line with
             local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result),
             hepatitis C. Patients with a past or resolved HBV infection (defined as the presence
             of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients
             positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction
             is negative for HCV RNA.

          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of
             durvalumab. Note: Patients, if enrolled, should not receive live vaccine whilst
             receiving durvalumab and up to 30 days after the last dose of durvalumab.

          -  Known allergy or hypersensitivity to any of the study/investigational drugs or any of
             the study/investigational drug excipients and/or radiochemotherapy with 5-FU and
             Mitomycin C.

          -  Female patients who are pregnant or breastfeeding or male or female patients of
             reproductive potential who are not willing to employ effective birth control from
             screening to 90 days after the last dose of durvalumab.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

, +49 69 6301-5130, [email protected]

Location Countries

Germany

Location Countries

Germany

Administrative Informations


NCT ID

NCT04230759

Organization ID

RADIANCE

Secondary IDs

2018-003005-25

Responsible Party

Principal Investigator

Study Sponsor

Goethe University


Study Sponsor

, , 


Verification Date

June 2021